Iščem...
Iskalni niz je ali predolg ali pa vsebuje preveč besed.
Prevodi: sl > en
1–50/54
toksikološko preskušanje
1 Končna redakcija
CELEX: 32004L0024
Direktiva 2001/83/ES [4] zahteva, da mora biti vlogi za izdajo dovoljenja za promet z zdravilom priložena dokumentacija, ki vsebuje podatke in listine, ki se nanašajo zlasti na rezultate fizikalno-kemijskih, bioloških ali mikrobioloških preskusov ter farmakološko-toksikoloških preskusov in kliničnih preskušanj, opravljenih na zdravilu in s tem dokazati kakovost, varnost in učinkovitost zdravila.
Directive 2001/83/EC(4) requires that applications for authorisation to place a medicinal product on the market have to be accompanied by a dossier containing particulars and documents relating in particular to the results of physico-chemical, biological or microbiological tests as well as pharmacological and toxicological tests and clinical trials carried out on the product and thus proving its quality, safety and efficacy.
2 Pravna redakcija
finance
CELEX: 32003L0063
ANALIZNI, FARMAKOLOŠKO-TOKSIKOLOŠKI IN KLINIČNI STANDARDI TER PROTOKOLI ZA PRESKUŠANJE ZDRAVIL
ANALYTICAL, PHARMACOTOXICOLOGICAL AND CLINICAL STANDARDS AND PROTOCOLS IN RESPECT OF THE TESTING OF MEDICINAL PRODUCTS
3 Pravna redakcija
DRUGO
predlagatelju ni treba predložiti rezultatov toksikoloških in farmakoloških preskusov ter kliničnih preskušanj, v primeru, če lahko dokaže, da:
the applicant shall not be required to provide the results of toxicological and pharmacological tests and clinical trials if he can demonstrate:
4 Pravna redakcija
finance
CELEX: 32003L0063
Če so rezultati, dobljeni v času preskušanj, nepričakovani, je treba opraviti dodatne predklinične toksikološke in farmakološke preskuse, ter jih ponovno preučiti.
Should unexpected results occur during the course of the trials, further pre clinical toxicological and pharmacological tests must be undertaken and reviewed.
5 Pravna redakcija
finance
CELEX: 32003L0063
b) Pred kliničnimi preskušanji je vedno treba opraviti ustrezne farmakološke in toksikološke preskuse, ki se izvedejo na živalih v skladu z zahtevami modula 4 te priloge.
b) Clinical trials must always be preceded by adequate pharmacological and toxicological tests, carried out on animals in accordance with the requirements of Module 4 of this Annex.
6 Pravna redakcija
finance
CELEX: 32003L0063
Zlasti je treba navesti vse pomembne podrobnosti o vseh nepopolnih ali opuščenih farmakološko-toksikoloških ali kliničnih preskusih ali preskušanjih zdravila in/ali dokončanih preskušanjih v zvezi s terapevtskimi indikacijami, ki jih vloga ne zajema.
In particular, all relevant details shall be given of any incomplete or abandoned pharmaco-toxicological or clinical test or trial relating to the medicinal product and/or completed trials concerning therapeutic indications not covered by the application.
7 Pravna redakcija
DRUGO
Obseg spremljanja skladnosti bi moral biti določen tako glede na kategorije kemikalij kot tudi glede na tipe preskušanja, na primer, fizikalna, kemijska, toksikološka in/ali ekotoksikološka,
The scope of the monitoring for compliance should be defined, both with respect to the categories of chemicals and to the types of tests subject to it, for example, physical, chemical, toxicological and/or ecotoxicological,
8 Pravna redakcija
DRUGO
Pristojni organi morajo izdelati poročilo o oceni zdravila ter komentarje o dokumentaciji glede rezultatov analitskih in farmakološko toksikoloških preskusov ter kliničnih preskušanj za zadevno zdravilo za uporabo v veterinarski medicini.
The competent authorities shall draw up an assessment report and comments on the dossier as regards the results of the analytical and pharmacotoxicological tests and the clinical trials of the veterinary medicinal product concerned.
9 Pravna redakcija
DRUGO
V ta namen mora upoštevati obseg ter trajanje izpostavljenosti okolja zdravilu ter informacije, pridobljene med izvajanjem ostalih preskusov in preskušanj, ki jih zahteva ta direktiva, o fizikalno-kemijskih, farmakoloških in/ali toksikoloških lastnostih spojine.
For this purpose, he shall consider the extent and duration of exposure of the environment to the product, and the information about the physical/chemical, pharmacological and/or toxicological properties of the compound obtained during the conduct of the other tests and trials required by this Directive.
10 Pravna redakcija
DRUGO
Direktiva Sveta 75/318/EGS z dne 20. maja 1975 o približevanju zakonodaje držav članic v zvezi z analiznimi, farmakološko-toksikološkimi in kliničnimi standardi in protokoli za preskušanje zdravil (UL št. L 147, 9. 6. 1975, str. 1), kakor je bila spremenjena z:
Council Directive 75/318/EEC of 20 May 1975 on the approximation of the laws of the Member States relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of medicinal products (OJ No L 147, 9.6.1975, p. 1), as amended by:
11 Pravna redakcija
promet
Direktiva Sveta 87/19/EGS z dne 22. decembra 1986 o spremembi Direktive 75/318/EGS o približevanju zakonodaj držav članic, ki se nanašajo na analitične, farmakološko-toksikološke in klinične standarde in protokole za preskušanje lastniških zdravil, ter spremembe Direktive
Council Directive 87/19/EEC of 22 December 1986 amending Directive 75/318/EEC on the approximation of the laws of the Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of proprietary medicinal products and amendments thereto
12 Pravna redakcija
promet
Direktiva Sveta 87/20/EGS z dne 22. decembra 1986 o spremembi Direktive 81/852/EGS o približevanju zakonodaj držav članic, ki se nanašajo na analitične, farmakološko-toksikološke in klinične standarde in protokole za preskušanje veterinarskih zdravil, ter spremembe Direktive
Council Directive 87/20/EEC of 22 December 1986 amending Directive 81/852/EEC on the approximation of the laws of the Member States relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products and amendments thereto
13 Pravna redakcija
DRUGO
Direktiva Sveta 81/852/EGS z dne 28. septembra 1981 o približevanju zakonodaje držav članic v zvezi z analiznimi, farmakološko-toksikološkimi in kliničnimi standardi in protokoli za preskušanje veterinarskih zdravil (UL št. L 317, 6. 11. 1981, str. 16), kakor je bila spremenjena z:
Council Directive 81/852/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products (OJ No L 317, 6.11.1981, p. 16), as amended by:
14 Pravna redakcija
finance
CELEX: 32003L0063
Kadar je zdravilo predvideno za drugačno terapevtsko uporabo ali je v drugi farmacevtski obliki, ali se bo dajalo po različnih poteh ali v različnih odmerkih ali z različnim odmerjanjem, se predložijo rezultati ustreznih toksikoloških in farmakoloških preskusov in/ali kliničnih preskušanj.
Where a medicinal product is intended for a different therapeutic use or presented in a different pharmaceutical form or to be administered by different routes or in different doses or with a different posology, the results of appropriate toxicological and pharmacological tests and/or of clinical trials shall be provided.
15 Pravna redakcija
promet
Direktiva Komisije 91/507/EGS z dne 19. julija 1991 o spremembi Priloge k Direktivi Sveta 75/318/EGS o približevanju zakonodaj držav članic, ki se nanašajo na analitične, farmakološko-toksikološke in klinične standarde in protokole za preskušanje lastniških zdravil, ter spremembe Direktive
Commission Directive 91/507/EEC of 19 July 1991 modifying the Annex to Council Directive 75/318/EEC on the approximation of the laws of the Member States relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of proprietary medicinal products and amendments thereto
16 Pravna redakcija
promet
Direktiva Komisije 92/18/EGS z dne 20. marca 1992 o spremembi Priloge k Direktivi Sveta 81/852/EGS o približevanju zakonodaj držav članic, ki se nanašajo na analitične, farmakološko-toksikološke in klinične standarde in protokole za preskušanje veterinarskih zdravil, ter spremembe Direktive
Commission Directive 92/18/EEC of 20 March 1992 modifying the Annex to Council Directive 81/852/EEC on the approximation of the laws of the Member States relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products and amendments thereto
17 Pravna redakcija
DRUGO
ki so bile uvedene z Direktivo Komisije 92/18/EGS z dne 20. marca 1992 o spremembi Priloge k Direktivi Sveta 81/852/EGS o približevanju zakonodaj držav članic v zvezi z analiznimi, farmako-toksikološkimi in kliničnimi standardi ter protokoli za preskušanje zdravil za uporabo v veterinarski medicini;
products introduced by Commission Directive 92/18/EEC of 20 March 1992 modifying the Annex to Council Directive 81/852/EEC on the approximation of laws of the Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products;
18 Pravna redakcija
DRUGO
Zaželeno je točneje predpisati primere, v katerih za pridobitev dovoljenja za promet z zdravili za uporabo v veterinarski medicini, ki je bistveno podobno inovativnemu zdravilu rezultati farmakoloških in toksikoloških preskusov ali kliničnih preskušanj niso potrebni, pri tem pa je treba zagotoviti, da inovativne oblike niso postavljene v slabši položaj.
It is advisable to stipulate more precisely the cases in which the results of pharmacological and toxicological tests or clinical trials do not have to be provided with a view to obtaining authorization for a veterinary medicinal product which is essentially similar to an innovative product, while ensuring that innovative forms are not placed at a disadvantage.
19 Pravna redakcija
DRUGO
v primeru novih zdravil za uporabo v veterinarski medicini, ki vsebujejo znane sestavine, ki dotlej v predlagani kombinaciji še niso bile uporabljane za terapevtske namene, je treba predložiti rezultate toksikoloških in farmakoloških preskusov ter kliničnih preskušanj, ki se nanašajo na zadevno kombinacijo, ni pa jih treba predložiti za vsako sestavino posebej.
in the case of new veterinary medicinal products containing known constituents not hitherto used in combination for therapeutic purposes, the results of toxicological and pharmacological tests and of clinical trials relating to that combination must be provided, but it shall not be necessary to provide the relevant documentation for each individual constituent.
20 Pravna redakcija
DRUGO
Država članica lahko uvede ali zadrži na svojem ozemlju posebna pravila za farmakološke in toksikološke preskuse ter klinično preskušanje za homeopatska zdravila za uporabo v veterinarski medicini, namenjena hišnim živalim in eksotičnim vrstam, ki niso namenjene za proizvodnjo živil, razen tistih iz člena 17(1), v skladu z načeli in značilnostmi homeopatije, ki se izvajajo v tej državi članici.
A Member State may introduce or retain in its territory specific rules for the pharmacological and toxicological tests and clinical trials of homeopathic veterinary medicinal products intended for pet animals and exotic species which are non food-producing other than those referred to in Article 17(1), in accordance with the principles and characteristics of homeopathy as practised in that Member State.
21 Pravna redakcija
DRUGO
ker je pri zdravilih za uporabo v veterini doseženo enako z direktivo Sveta 81/851/EGS z dne 28. septembra 1981 o približevanju zakonodaje držav članic v zvezi z zdravili za uporabo v veterini fn ektivo Sveta 81/852/EGS z dne 28. septembra 1981 o približevanju zakonodaje držav članic v zvezi z analiznimi, farmakološko-toksikološkimi in kliničnimi standardi in protokoli, ki se nanašajo na preskušanje zdravil za uporabo v veterini fn
Whereas in the case of veterinary medicinal products, the same results have been achieved by Council Directive 81/85 I/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to veterinary medicinal products (1) and by Council Directive 81/852/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products (2);
22 Pravna redakcija
DRUGO
ker je treba upoštevati predpise Skupnosti o veterinarskih zdravilih in zlasti Direktivo Sveta 81/851/EGS z dne 28. septembra 1981 o približevanju zakonov držav članic o veterinarskih zdravilih fn in Direktivo Sveta 81/852/EGS z dne 28. septembra 1981 o približevanju zakonov držav članic o analitskih, farmako-toksikoloških in kliničnih standardih ter protokolih o preskušanju veterinarskih zdravil fn, kakor je bila spremenjena z Direktivo 87/20/EGS fn;
Whereas Community rules regarding veterinary medicinal products, and in particular Council Directive 81/851/EEC of 28 September 1981 on the approximation of the laws of Member States relating to veterinary medicinal products fn, and Council Directive 81/852/EEC of 28 September 1981 on the approximation of the laws of Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products fn, as amended by Directive 87/20/EEC fn, should be taken into account;
23 Pravna redakcija
finance
CELEX: 32003L0063
Raziskovalec se mora seznaniti z zaključki farmakoloških in toksikoloških študij in vlagatelj mu mora predložiti vsaj brošuro za raziskovalca, ki je sestavljena iz vseh pomembnih informacij, ki so znane pred začetkom kliničnega preskušanja, vključno s kemijskimi, farmacevtskimi in biološkimi podatki, toksikološkimi, farmakokinetičnimi in farmakodinamičnimi podatki pri živalih ter rezultati prejšnjih kliničnih preskušanj, z ustreznimi podatki, ki utemeljujejo vrsto, obseg in trajanje predlaganega preskušanja;
The investigator must acquaint himself with the conclusions drawn from the pharmacological and toxicological studies and hence the applicant must provide him at least with the investigator's brochure, consisting of all the relevant information known prior to the onset of a clinical trial including chemical, pharmaceutical and biological data, toxicological, pharmaco-kinetic and pharmaco-dynamic data in animals and the results of earlier clinical trials, with adequate data to justify the nature, scale and duration of the proposed trial;
24 Pravna redakcija
DRUGO
ker je treba po znanstveni presoji, ki jo opravi Odbor za zdravila za uporabo v veterinarski medicini, sprejeti najvišje dovoljene količine zaostankov po hitrem postopku, ki zagotavlja tesno sodelovanje med Komisijo in državami članicami v odboru, ustanovljenim na podlagi Direktive Sveta 81/852/EGS z dne 28. septembra 1981 o približevanju zakonodaj držav članic v zvezi z analiznimi, farmako-toksikološkimi in kliničnimi standardi ter protokoli za preskušanje zdravil za uporabo v veterinarski medicini fn, kakor je bila nazadnje spremenjena z Direktivo 87/20/EGS fn;
Whereas, after scientific assessment by the Committee for Veterinary Medicinal Products, maximum residue levels must be adopted by a rapid procedure which ensures close cooperation between the Commission and the Member States through the Committee set up under Council Directive 81/852/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products (4), as last amended by Directive 87/20/EEC (5);
25 Pravna redakcija
DRUGO
ker so pri zdravilih za ljudi merila kakovosti, varnosti in učinkovitosti v znatni meri usklajena z direktivo Sveta 65/65/EGS z dne 26. januarja 1965 o približevanju določb zakonov ali drugih predpisov, ki se nanašajo na zdravila fn ugo direktivo Sveta 75/319/EGS z dne 20. maja 1975 o približevanju določb zakonov in drugih predpisov, ki se nanašajo na lastniška zdravila fn rektivo Sveta 75/318/EGS z dne 20. maja 1975 o približevanju zakonodaje držav članic v zvezi z analiznimi farmakološko-toksikološkimi in kliničnimi standardi in protokoli, ki se nanašajo na preskušanje zdravil za uporabo v veterini fn
Whereas, in the case of medicinal products for human use, the criteria of quality, safety and efficacy have been extensively harmonized by Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (5), and the Second Council Directive 75/319/EEC of 20 May 1975 on the approximation of provisions laid down by law, regulation and administrative action relating to proprietary medicinal products (6), and by Council Directive 75/318/EEC of 20 May 1975 on the approximation of the laws of the Member States relating to analytical pharmaco-toxicological and clinical standards and protocols in respect of the testing of medicinal products (7);
26 Pravna redakcija
DRUGO
Direktiva Sveta 81/851/EGS z dne 28. septembra 1981 o prilagajanju zakonodaj držav članic, ki se nanaša na zdravila za uporabo v veterinarski medicini( fn ), Direktiva Sveta 81/852/EGS z dne 28. Septembra 1981 o prilagajanju zakonodaj držav članic, ki se nanaša na analitske, farmakološko-toksikološke in klinične standarde ter protokole v zvezi s preskušanjem zdravil za uporabo v veterinarski medicini( fn ), Direktiva Sveta 90/677/EGS z dne 13. decembra 1990 o razširitvi področje uporabe Direktive 81/851/EGS o prilagajanju zakonodaj držav članic, ki se nanaša na zdravila za uporabo v veterinarski medicini in o določitvi dodatnih določb za imunološka zdravila za uporabo v veterinarski medicini( fn ), in Direktiva Sveta 92/74/EGS z dne 22. septembra 1992 o razširitvi področje uporabe Direktive 81/851/EGS o prilagajanju zakonov in drugih predpisov, ki se nanašajo na zdravila za uporabo v veterinarski medicini in ki določa dodatne predpise za homeopatska zdravila za uporabo v veterinarski medicini( fn ), so bile pogosto in znatno spremenjene;
Council Directive 81/851/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to veterinary medicinal products (3), Council Directive 81/852/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products (4), Council Directive 90/677/EEC of 13 December 1990 extending the scope of Directive 81/851/EEC on the approximation of the laws of the Member States relating to veterinary medicinal products and laying down additional provisions for immunological veterinary medicinal products (5), and Council Directive 92/74/EEC of 22 September 1992 widening the scope of Directive 81/851/EEC on the approximation of provisions laid down by law, regulation or administrative action relating to veterinary medicinal products and laying down additional provisions on homeopathic veterinary medicinal products (6) have been frequently and substantially amended;
27 Prevajalska redakcija
RS
EMEA
Pri miših, podganah in psih so bila toksikološka preskušanja opravljena samo z darunavirjem, pri podganah in psih pa v kombinaciji z ritonavirjem.
Animal toxicology studies have been conducted at exposures up to clinical exposure levels with darunavir alone, in mice, rats and dogs and in combination with ritonavir in rats and dogs.
28 Prevajalska redakcija
izobraževanje
CELEX: 32001L0083
se od vlagatelja ne zahteva predložitev rezultatov toksikoloških in farmakoloških preskusov ali rezultatov kliničnih preskušanj, če lahko dokaže, da:
The applicant shall not be required to provide the results of toxicological and pharmacological tests or the results of clinical trials if he can demonstrate:
29 Prevajalska redakcija
izobraževanje
CELEX: 32001L0083
Zlasti se podajo vsi pomembni podatki za vsak nepopoln ali izpuščen farmakološko-toksikološki ali klinični preskus ali preskušanje v zvezi z zdravilom.
In particular, all relevant details shall be given of any incomplete or abandoned pharmacotoxicological or clinical test or trial relating to the medicinal product.
30 Prevajalska redakcija
izobraževanje
CELEX: 32001L0083
Pred kliničnimi preskušanji je vedno treba opraviti ustrezne farmakološke in toksikološke preskuse, ki se izvedejo na živalih v skladu z zahtevami dela 3 te Priloge.
Clinical trials must always be preceded by adequate pharmacological and toxicological tests, carried out on animals in accordance with the requirements of Part 3 of this Annex.
31 Prevajalska redakcija
izobraževanje
CELEX: 32003L0063
Pred kliničnimi preskušanji je vedno treba opraviti ustrezne farmakološke in toksikološke preskuse, ki se izvedejo na živalih v skladu z zahtevami modula 4 te priloge.
Clinical trials must always be preceded by adequate pharmacological and toxicological tests, carried out on animals in accordance with the requirements of Module 4 of this Annex.
32 Prevajalska redakcija
izobraževanje
CELEX: 32001L0083
Če so rezultati, pridobljeni v času preskušanj, nepričakovani, je treba opraviti dodatne predklinične toksikološke in farmakološke preskuse ter jih ponovno preučiti.
Should unexpected results occur during the course of the trials, further preclinical toxicological and pharmacological tests must be undertaken and reviewed.
33 Prevajalska redakcija
izobraževanje
CELEX: 32001L0083
Pristojni organi izdelajo poročilo o oceni zdravila in pripombe na dosje v zvezi z rezultati analiznih in farmakološko-toksikoloških preskusov ter kliničnih preskušanj zadevnega zdravila.
The competent authorities shall draw up an assessment report and comments on the dossier as regards the results of the analytical and pharmacotoxicological tests and the clinical trials of the medicinal product concerned.
34 Prevajalska redakcija
izobraževanje
CELEX: 32001L0020
formatu in vsebini zahteve iz odstavka 2 ter dokumentaciji o kakovosti in izdelavi zdravila v preskušanju, kakršnih koli toksikoloških in farmakoloških preskusih, protokolu in kliničnih informacijah o zdravilu v preskušanju vključno z brošuro za raziskovalca, ki se mora predložiti v podporo zahtevi;
the format and contents of the request referred to in paragraph 2 as well as the documentation to be submitted to support that request, on the quality and manufacture of the investigational medicinal product, any toxicological and pharmacological tests, the protocol and clinical information on the investigational medicinal product including the investigator's brochure;
35 Prevajalska redakcija
izobraževanje
CELEX: 32001L0083
Direktiva Sveta 75/318/EGS z dne 20. maja 1975 o približevanju zakonodaje držav članic v zvezi z analiznimi, farmakološko-toksikološkimi in kliničnimi standardi ter protokoli, ki se nanašajo na preskušanje lastniških zdravil [4],
Council Directive 75/318/EEC of 20 May 1975 on the approximation of the laws of Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of proprietary medicinal products(4),
36 Prevajalska redakcija
izobraževanje
CELEX: 31994D0358
2 Direktiva Sveta 75/318/EGS z dne 20. maja 1975 o približevanju zakonodaje držav članic, ki se nanaša na analizne, farmakološko-toksikološke in klinične standarde ter protokole v zvezi s preskušanjem lastniških zdravil (UL L 147, 9.6.1975, str. 1).
Council Directive 75/318/EEC of 20 May 1975 on the approximation of the laws of Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of proprietary medicinal products (OJ No L 147, 9.6.1975, p. 1).
37 Prevajalska redakcija
izobraževanje
CELEX: 31994D0358
3 Direktiva Sveta 81/852/EGS z dne 28. septembra 1981 o približevanju zakonodaje držav članic, ki se nanaša na analizne, farmakološko-toksikološke in klinične standarde ter protokole v zvezi s preskušanjem veterinarskih zdravil (UL L 317, 6.11.1981, str. 16).
Council Directive 81/852/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products (OJ No L 317, 6.11.1981, p. 16).
38 Prevajalska redakcija
izobraževanje
CELEX: 32001L0020
Zaščito preizkušancev kliničnega preskušanja zagotavljajo ocena tveganja, ki temelji na rezultatih toksikoloških poskusov pred kakršnim koli kliničnim preskušanjem, pregled odborov za etiko in pristojnih organov držav članic ter pravila o varstvu osebnih podatkov.
The clinical trial subject's protection is safeguarded through risk assessment based on the results of toxicological experiments prior to any clinical trial, screening by ethics committees and Member States' competent authorities, and rules on the protection of personal data.
39 Prevajalska redakcija
izobraževanje
Direktivo Komisije 1999/82/ES z dne 8. septembra 1999 o spremembi Priloge k Direktivi Sveta 75/318/EGS o približevanju zakonodaj držav članic v zvezi z analiznimi, farmakološko-toksikološkimi in kliničnimi standardi in protokoli za preskušanje zdravil [5] je treba vključiti v Sporazum.
Commission Directive 1999/82/EC of 8 September 1999 amending the Annex to Council Directive 75/318/EEC on the approximation of the laws of the Member States relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of medicinal products(5) is to be incorporated into the Agreement.
40 Prevajalska redakcija
izobraževanje
Direktivo Komisije 1999/83/ES z dne 8. septembra 1999 o spremembi Priloge k Direktivi Sveta 75/318/EGS o približevanju zakonodaj držav članic v zvezi z analiznimi, farmakološko-toksikološkimi in kliničnimi standardi in protokoli za preskušanje zdravil [6] je treba vključiti v Sporazum -
Commission Directive 1999/83/EC of 8 September 1999 amending the Annex to Council Directive 75/318/EEC on the approximation of the laws of the Member States relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of medicinal products(6) is to be incorporated into the Agreement,
41 Prevajalska redakcija
izobraževanje
CELEX: 32001L0020
Direktiva Sveta 75/318/EGS z dne 20. maja 1975 o približevanju zakonodaje držav članic v zvezi z analiznimi, farmakološko-toksikološkimi in kliničnimi standardi in protokoli, ki se nanašajo na preskušanje zdravil [5] določa enotna pravila o sestavi dokumentacije, vključno z njeno obliko.
Council Directive 75/318/EEC of 20 May 1975 on the approximation of the laws of Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of medicinal products(5) lays down uniform rules on the compilation of dossiers including their presentation.
42 Prevajalska redakcija
izobraževanje
CELEX: 32001L0083
Če gre za nova zdravila, ki vsebujejo znane sestavine, dotlej še neuporabljene v kombinaciji za terapevtske namene, je treba predložiti rezultate toksikoloških in farmakoloških preskusov in kliničnih preskušanj za zadevno kombinacijo, ni pa jih treba predložiti za vsako posamezno sestavino.
In the case of new medicinal products containing known constituents not hitherto used in combination for therapeutic purposes, the results of toxicological and pharmacological tests and of clinical trials relating to that combination must be provided, but it shall not be necessary to provide references relating to each individual constituent.
43 Prevajalska redakcija
izobraževanje
CELEX: 32001L0083
Kadar je zdravilo namenjeno za drugačno terapevtsko uporabo, ki se razlikuje od uporabe zdravil, ki so že v prometu, ali bo način jemanja drugačen ali v drugačnih odmerkih, je treba predložiti rezultate ustreznih toksikoloških in farmakoloških preskusov in/ali ustreznih kliničnih preskušanj.
However, where the medicinal product is intended for a different therapeutic use from that of the other medicinal products marketed or is to be administered by different routes or in different doses, the results of appropriate toxicological and pharmacological tests and/or of appropriate clinical trials must be provided.
44 Prevajalska redakcija
izobraževanje
CELEX: 22001D0065
Direktiva Sveta 1999/104/ES z dne 22. decembra 1999 o spremembi Priloge k Direktivi Sveta 81/852/EGS o približevanju zakonodaj držav članic v zvezi z analiznimi, farmakološko-toksikološkimi in kliničnimi standardi in protokoli za preskušanje veterinarskih zdravil [2] mora biti vključena v Sporazum -
Commission Directive 1999/104/EC of 22 December 1999 amending the Annex to Council Directive 81/852/EEC on the approximation of the laws of the Member States relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products(2) is to be incorporated into the Agreement,
45 Prevajalska redakcija
izobraževanje
CELEX: 32001L0083
Država članica na svojem ozemlju lahko uvede ali ohrani posebna pravila za toksikološke in farmakološke preskuse ter klinična preskušanja homeopatskih zdravil, ki se razlikujejo od navedenih v členu 14(1) v skladu z načeli in značilnostmi homeopatske dejavnosti, kakor se opravlja v tej državi članici.
A Member State may introduce or retain in its territory specific rules for the toxicological and pharmacological tests and clinical trials of homeopathic medicinal products other than those referred to in Article 14(1) in accordance with the principles and characteristics of homeopathy as practised in that Member State.
46 Prevajalska redakcija
izobraževanje
CELEX: 31992R0762
ker je treba spremeniti Prilogo V k Uredbi (EGS) št. 2377/90, tako da bo upoštevala spremembe zahtev za preskušanje zdravil za uporabo v veterinarski medicini, ki so bile uvedene z Direktivo Komisije 92/18/EGS z dne 20. marca 1992 o spremembi Priloge k Direktivi Sveta 81/852/EGS o približevanju zakonodaj držav članic v zvezi z analiznimi, farmako-toksikološkimi in kliničnimi standardi ter protokoli za preskušanje zdravil za uporabo v veterinarski medicini;
Whereas it is necessary to amend Annex V to Regulation (EEC) No 2377/90 to take account of the changes to the requirements for the testing of veterinary medicinal products introduced by Commission Directive 92/18/EEC of 20 March 1992 modifying the Annex to Council Directive 81/852/EEC on the approximation of laws of the Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products;
47 Prevajalska redakcija
izobraževanje
CELEX: 32001L0083
Direktiva Sveta 65/65/EGS z dne 26. januarja 1965 o približevanju določb zakonov ali drugih predpisov o lastniških zdravilih [3], Direktiva Sveta 75/318/EGS z dne 20. maja 1975 o približevanju zakonodaje držav članic v zvezi z analiznimi, farmakološko-toksikološkimi in kliničnimi standardi ter protokoli, ki se nanašajo na preskušanje lastniških zdravil [4],
Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products(3), Council Directive 75/318/EEC of 20 May 1975 on the approximation of the laws of Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of proprietary medicinal products(4),
48 Prevajalska redakcija
izobraževanje
CELEX: 32001L0083
Na podlagi izkušenj je priporočljivo bolj podrobno določiti primere, pri katerih rezultatov toksikoloških in farmakoloških preskusov ali kliničnih preskušanj ni treba predložiti v vlogi za pridobitev dovoljenja za promet z zdravilom, ki je bistveno podobno zdravilu, ki je že pridobilo dovoljenje za promet, pri tem pa je treba zagotoviti, da inovativna podjetja ne bodo prikrajšana.
Experience has shown that it is advisable to stipulate more precisely the cases in which the results of toxicological and pharmacological tests or clinical trials do not have to be provided with a view to obtaining authorization for a medicinal product which is essentially similar to an authorized product, while ensuring that innovative firms are not placed at a disadvantage.
49 Prevajalska redakcija
izobraževanje
CELEX: 32004L0024
Direktiva 2001/83/ES [4] zahteva, da mora biti vlogi za izdajo dovoljenja za promet z zdravilom priložena dokumentacija, ki vsebuje podatke in listine, ki se nanašajo zlasti na rezultate fizikalno-kemijskih, bioloških ali mikrobioloških preskusov ter farmakološko-toksikoloških preskusov in kliničnih preskušanj, opravljenih na zdravilu in s tem dokazati kakovost, varnost in učinkovitost zdravila.
Directive 2001/83/EC(4) requires that applications for authorisation to place a medicinal product on the market have to be accompanied by a dossier containing particulars and documents relating in particular to the results of physico-chemical, biological or microbiological tests as well as pharmacological and toxicological tests and clinical trials carried out on the product and thus proving its quality, safety and efficacy.
50 Prevajalska redakcija
izobraževanje
CELEX: 31993R2309
ker je pri zdravilih za uporabo v veterinarski medicini doseženo enako z Direktivo Sveta 81/851/EGS z dne 28. septembra 1981 o približevanju zakonodaje držav članic v zvezi z zdravili za uporabo v veterini 4 in z Direktivo Sveta 81/852/EGS z dne 28. septembra 1981 o približevanju zakonodaje držav članic v zvezi z analiznimi, farmakološko-toksikološkimi in kliničnimi standardi in protokoli, ki se nanašajo na preskušanje zdravil za uporabo v veterini 5;
Whereas in the case of veterinary medicinal products, the same results have been achieved by Council Directive 81/851/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to veterinary medicinal products (7) and by Council Directive 81/852/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products (8);
Prevodi: sl > en
1–50/54
toksikološko preskušanje